Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard Authors: Ieuan Edward Shepherd Evans, Daniel Smith, Daniel Henderson, Timothy Riddles, Philip Masel, Vanessa Moore, Andrew J Burke, Rachel M Thomson, David W Reid Published: 2025 ABSTRACT AbstractBackgroundThe prevalence of infection with non-tuberculous mycobacteria (NTM) has been increasing in people with cystic fibrosis (pwCF) over the past 30 years. Emerging reports of beneficial effects of CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), on the rates of NTM acquisition and persistence are encouraging. In this observational study, we evaluate the impact of the introduction of ETI on the prevalence of NTM infection within a cohort of pwCF living in sub-tropical Queensland, Australia.MethodsWe examined the impact of ETI introduction on rates of NTM isolation in pwCF attending an adult CF centre and two large regional clinics providing CF care. Data on NTM infection were collected for a minimum of 2 years pre- and post-initiation of ETI.ResultsIn total, 271 (84.2%) were commenced on ETI with 33 (12.2%) of these pwCF isolating an NTM species on one or more occasion. The number of pwCF isolating Mycobacterium abscessus (Mabs) remained static across the 4-year period of analysis. However, there was a trend towards declining numbers of pwCF isolating either Mycobacterium intracellulare or other NTM species across the surveillance period.ConclusionsETI therapy was not associated with reduced rates of NTM isolation from sputum over the first 2 years of treatment. However, at a species level, two distinct patterns of change were seen with a trend towards a reduction in the isolation of M. intracellulare, while the rates of Mabs isolation remained unchanged. The reasons for this remain unclear at present but highlight the need for ongoing vigilance with screening for NTM in the setting of ETI therapy.Keywords: Cystic Fibrosis, Atypical Mycobacterial Infection, Respiratory Infection, Opportunist lung infections WHAT IS ALREADY KNOWN ON THIS TOPIC To date, limited published analyses and case reports suggest the introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with a reduced prevalence of non-tuberculous mycobacteria (NTM) in certain individuals. To date, limited published analyses and case reports suggest the introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with a reduced prevalence of non-tuberculous mycobacteria (NTM) in certain individuals. WHAT THIS STUDY ADDS This study provides further insights into the effect ETI has on the nature of NTM isolation in people with cystic fibrosis (CF). In contrast to the current published literature, no significant decline in the rate of NTM isolation in our cohort, particularly Mycobacterium abscessus, was noted. This study provides further insights into the effect ETI has on the nature of NTM isolation in people with cystic fibrosis (CF). In contrast to the current published literature, no significant decline in the rate of NTM isolation in our cohort, particularly Mycobacterium abscessus, was noted. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study highlights the requirement for ongoing vigilance in relation to pathogens like NTM in an era of general de-escalation of therapeutic interventions for people with CF following the introduction of ETI. This study highlights the requirement for ongoing vigilance in relation to pathogens like NTM in an era of general de-escalation of therapeutic interventions for people with CF following the introduction of ETI. Introduction The prevalence of infection with non-tuberculous mycobacteria (NTM) has been increasing in people with cystic fibrosis (pwCF) since the mid-1990s, when NTM first started to be recognised as pathogens in pwCF.1 The factors that govern this remain unclear, but the increase is concerning given the burden of morbidity associated with NTM infections. A recent meta-analysis showed a global prevalence rate of NTM in pwCF between 2010 and 2019 of around 7.9% with an annual increase in the USA over the same period of 3.5% per annum.2 3 The predominant NTM organisms isolated in pwCF are Mycobacterium abscessus complex (Mabs) and M. avium complex (MAC). While other NTM species are isolated, Mabs and MAC are most typically associated with the development of NTM pulmonary disease (NTM-PD), with Mabs associated with an accelerated decline in FEV1, with infection also impacting on suitability for lung transplantation.4,6 The propensity for NTM infection in pwCF is likely to be contributed to by a favourable lung microenvironment and dysfunction or exhaustion of key components of host immunity. However, there is hope that the introduction of highly effective CF transmembrane regulator (CFTR) modulators may reduce the rate of NTM acquisition by pwCF, thereby potentially reducing the disease burden posed by these organisms. Emerging reports of beneficial effects of CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor (ETI), on the rate of NTM acquisition and persistence are encouraging.7 Certainly, treatment with CFTR modulators has been shown to impact the microbiome of pwCF in relation to other organisms, particularly Pseudomonas aeruginosa, presumably because of improvements in neutrophil and macrophage function, combined with improved mucociliary clearance.8 9 However, published data demonstrates that P. aeruginosa persists in the lungs of most pwCF, although in reduced abundance, despite the initiation of ETI.10 Whether this is the case for NTM remains unknown at present, but there are anecdotal case reports of pwCF with previously intractable NTM-PD caused by Mabs who have shown a remarkable improvement, including potential eradication, following commencement of the ETI.11 In this study, we evaluate the impact on the rate of NTM infection of the introduction of ETI within a unique cohort of pwCF living in sub-tropical Queensland, Australia, where there is an existing relatively high background prevalence of NTM infection in both the CF and non-CF population.12 Methods We evaluated the impact of the initiation of ETI on the rates of NTM isolation in sputum, obtained either via spontaneous expectoration or induction, in pwCF attending a state-wide adult CF service incorporating two large regional CF clinics providing clinical care to pwCF living in a geographical region seven times the size of the UK. The study was conducted at the largest adult CF service in Queensland, Australia, the Adult Cystic Fibrosis Centre (ACFC) at The Prince Charles Hospital (TPCH), Brisbane. The geographic distribution of the 322 pwCF under this service includes northern New South Wales, Queensland and Northern Territories with the predominant centre in Brisbane and two outreach services in Townsville and Cairns. Data were collected retrospectively for the 2 years prior and then prospectively for 2 years post-ETI initiation. Post-ETI initiation data collection formed part of a sub-analysis as part of a larger prospective study on the clinical impact of ETI on all pwCF commenced on ETI at our centre. Sputum collection was carried out at scheduled outpatient clinic appointments pre-ETI (usually at 3 monthly intervals) and at 1, 3, 6, 12, 18 and 24 months post-ETI initiation and/or at ad hoc clinic attendances or inpatient stays, for example, during periods of exacerbation. Sputum processing was carried out by Pathology Queensland using the following protocol. Sputum samples were liquefied using sputasol (0.1% dithiothreitol solution) and decontaminated with sodium hydroxide (4%). After neutralisation with phosphoric acid (1M), samples were centrifuged to concentrate any mycobacteria. Aliquots of the processed specimens were inoculated onto Lowenstein-Jensen media and into Bactec MGIT 960 vials with Cepacia supplement for mycobacterial culture. All pwCF in this study were over the age of 18 years with a confirmed diagnosis of CF. Inclusion criteria for analysis in the study required an isolation of an NTM species on two or more occasions during the 4-year study period and completion of a full 24 months of ETI therapy. Data on NTM infection status were collected for a minimum period of 2 years prior to ETI initiation and 2 years following ETI initiation. Following the initiation of ETI, sustained culture negativity was defined as at least three negative satisfactory sputum samples collected over the subsequent 12-month period. Demographic data collected for each pwCF included: age; sex; CFTR mutation profile; CFTR modulator therapy (prior to ETI); lung disease severity (FEV1, % predicted); presence of other organisms such as P. aeruginosa; pancreatic insufficiency; CF-related diabetes; CF liver disease; date of initial isolation of NTM; NTM subspecies (where relevant); and whether previous NTM treatment had been successful or unsuccessful. Ethical approval for the study was obtained from the Metro North Health Human Research Ethics Committee (HREC/2019/QPCH/46169). Written informed consent was obtained for all participants involved in this study. There was no patient/public involvement in the design and/or conduct of this study. Statistical analysis Statistical analysis was carried out using simple t-test and/or ordinary one-way analysis of variance (ANOVA) using Tukey’s multiple comparisons tests for the analysis of different NTM groups, microbiological samples, FEV1 data and body mass index (BMI) data sets. The analysis was conducted using the GraphPad Prism v.10.2.1 (339). Results Within the TPCH CF cohort of 322 pwCF, 271 (84.2%) had been commenced on ETI and formed the basis of the study population. In total, 33 (12.2%) of these pwCF isolated an NTM species on one or more occasion over the 4-year study period, with one pwCF isolating both Mabs and M. simiae. Seventeen pwCF isolated Mabs, with four of these pwCF excluded from the analysis due to having only isolated Mabs on a single sputum sample. The remaining 13 pwCF had isolated Mabs on at least two or more occasions in the 2 years pre-initiation of ETI or 2 years after commencing ETI therapy. Fifteen pwCF isolated M. intracellulare or another NTM species. Nine of these pwCF were excluded from the analysis having isolated M. intracellulare or another NTM species from sputum on one occasion only. The remaining six pwCF had been established on ETI for at least 2 years and had isolated either M. intracellulare or another NTM species over the 2 years leading up to the initiation of ETI or 2 years after commencing ETI therapy. One pwCF isolated both Mabs and M. simiae on at least two or more occasions in the 2 years pre-initiation of ETI or 2 years after commencing ETI therapy (figure 1). The other NTM species isolated included M. fortuitum and M. stomatepiae. Of the pwCF not established on ETI, there were only three who isolated an NTM on two or more occasions during this period, two were not on modulators owing to severe liver disease (both Mabs) and one was established on tezacaftor/ivacaftor and ivacaftor (Symdeko) (M. intracellulare). Flow chart highlighting the number of pwCF forming part of the study analysis. ACFC, Adult Cystic Fibrosis Centre; ETI, elexacaftor/tezacaftor/ivacaftor; M. abscessus, Mycobacterium abscessus; M. intracellulare, Mycobacterium intracellulare; NTM, non-tuberculous mycobacteria; pwCF, people with cystic fibrosis; TPCH, The Prince Charles Hospital. In the post-ETI commencement period, there were four new acquisitions of NTM species identified on at least two sputum cultures among pwCF commenced on ETI who had not previously isolated these pathogens, with three being Mabs and one M. fortuitum. Baseline lung function for these new acquisitions of NTM was as follows: (FEV1 (% predicted)), 3.4 (81.2%); 2.21 (50.5%); 1.87 (65.6%); and 1.77 (54.2%). The demographics of the pwCF in the cohort established on ETI with two or more isolates of an NTM species during the study period are highlighted in table 1. Table 1Demographics of pwCF attending TPCH ACFC at the time of initiation of ETI with either previous or ongoing isolation of NTM species over the 4-year study periodCharacteristicM. abscessus complex (n=13)M. intracellulare(n=3)Other NTM species (n=3)M. abscessus complex andM. simiae (n=1)Age (years)19–5021–5726–4921(mean 29.85, SD 9.59)(mean 33.67, SD 20.23)(mean 31.33, SD 6.2)–Male sex, n (%)7 (53.9%)3 (100%)3 (100%)–Mutation group, n (%) F508del/F508del9 (69.2%)1 (33.3%)2 (66.7%)– F508del/other4 (30.8%)2 (66.7%)1 (33.3%)1 (100%)Lung function (spirometry) FEV1, L/minute1.22–3.85(38.8–97.1%)1.76–2.69(39.3–66.2%)2.70–4.63(59.5–107.7%)2.75(83.5%) (% predicted)(mean 2.49)(mean 2.27)(mean 3.41)–Comorbidities – n (%) Pancreatic insufficiency13 (100%)3 (100%)3 (100%)– CFRD4 (30.7%)––– CFLD2 (15.4%)1 (33.3%)––Previous modulator treatment, n (%) Nil6 (46.2%)–1 (33.3%)1 (100%) Ivacaftor1 (7.7%)––– Lumacaftor/Ivacaftor5 (38.5%)2 (66.7%)2 (66.7%)– Tezacaftor/Ivacaftor3 (23.1%)2 (66.7%)1 (33.3%)–Previous NTM-PD treatment, n (%) Yes6 (46.2%)1 (33.3%)–– No5 (38.5%)2 (66.7%)3 (100%)1 (100%) Unknown2 (15.4%)–––Other colonising organisms, n (%) Nil regular–––1 (100%) Pseudomonas aeruginosa13 (100%)1 (33.3%)2 (66.7%)– Staphylococcus aureus8 (61.5%)1 (33.3%)2 (66.7%)– Aspergillus fumigatus3 (23.1%)2 (66.7%)–– Stenotrophomonas maltophilia1 (7.7%)––– Achromobacter sp.––1 (33.3%)–Age: range, mean and SD.ACFC, Adult Cystic Fibrosis Centre; CFLD, CF-related liver disease; CFRD, CF-related diabetes; ETI, elexacaftor/tezacaftor/ivacaftor; FEV1, forced expired volume in one second; M. abscessus, Mycobacterium abscessus; M. intracellulare, Mycobacterium intracellulare; M. simiae, Mycobacterium simiae; NTM-PD, non-tuberculous mycobacteria pulmonary disease; pwCF, people with cystic fibrosis; TPCH, The Prince Charles Hospital. Demographics of pwCF attending TPCH ACFC at the time of initiation of ETI with either previous or ongoing isolation of NTM species over the 4-year study period Age: range, mean and SD. ACFC, Adult Cystic Fibrosis Centre; CFLD, CF-related liver disease; CFRD, CF-related diabetes; ETI, elexacaftor/tezacaftor/ivacaftor; FEV1, forced expired volume in one second; M. abscessus, Mycobacterium abscessus; M. intracellulare, Mycobacterium intracellulare; M. simiae, Mycobacterium simiae; NTM-PD, non-tuberculous mycobacteria pulmonary disease; pwCF, people with cystic fibrosis; TPCH, The Prince Charles Hospital. There was no statistically significant difference in the total number of NTM sputum samples collected for the patient cohort when comparing the total number of samples collected across the 4-year period of analysis (p=0.81) (figure 2A). While there was the suggestion of a downward trend in the proportion of positive isolates of all NTM species from these sputum samples (figure 2B), this again failed to reach statistical significance (p=0.23), indicating the overall number of pwCF isolating NTM in our cohort remained unchanged. Sputum sampling and rate of NTM species isolated from sputum remain static despite initiation of ETI. No significant difference was noted in the isolation of Mabs, MAC and other NTM species isolation from sputum following initiation of ETI therapy. (A) Total number of mycobacterial sputum samples collected for pwCF with ≥2 isolates of NTM (n=20 owing to one pwCF isolating both Mabs/M. simiae). No statistically significant difference was seen between the total number of mycobacterial sputum samples collected across the 4 years of analysis. (B) Total number of positive isolates of NTM from sputum from pwCF with ≥2 isolates of NTM (n=20 owing to one pwCF isolating both Mabs/M. simiae). While a trend towards a reducing number of isolates of NTM in sputum was noted, it did not reach statistical significance. (C) No statistically significant difference was noted in the number of sputum cultures positive for Mabs following the introduction of ETI (n=14). (D) No statistically significant difference was noted in the number of sputum cultures positive for MAC and other NTM species following the introduction of ETI (n=7). However, there was a trend towards a decline in the number of M. intracellulare and other NTM species isolated from sputum when comparing the number of positive isolates from 2 years prior to ETI initiation to 1 year and 2 years post-ETI. Each coloured dot represents an individual pwCF. Statistical significance was evaluated using an ordinary one-way analysis of variance. ETI, elexacaftor/tezacaftor/ivacaftor; Mabs, Mycobacterium abscessus; MAC, M. avium complex; NTM, non-tuberculous mycobacteria; pwCF, people with cystic fibrosis. We further analysed these results by separating the cohort into those pwCF isolating Mabs and those isolating M. intracellulare and any other NTM (analysed collectively owing to the relatively small numbers of M. intracellulare positive pwCF in our cohort). The number of pwCF isolating Mabs remained static across the 4-year period of analysis (p=0.76) (figure 2C). However, while not reaching statistical significance (p=0.06), there was a trend towards declining numbers of pwCF isolating either M. intracellulare or other NTM species when comparing the number of NTM species isolated 2 years prior to ETI commencing with both 1 year and 2 years post-ETI therapy (figure 2D). Analysing the individual trajectories further (figure 3), of the 13 pwCF who isolated Mabs, four remained culture positive along with two pwCF experiencing novel acquisition. There was also one pwCF who had an apparent new transient infection around a year after starting ETI before culture converting shortly thereafter. Unfortunately, three pwCF were deemed to have an ‘unclear status’ (as marked by grey shadowing in figure 3) owing to a lack of microbiological/mycobacterial samples following ETI commencing to allow for a determination of culture status. Of the six pwCF isolating either M. intracellulare or another NTM species, there was one novel acquisition of M. fortuitum, with two pwCF again deemed to have an unclear culture status owing to a lack of microbiological samples. The pwCF who isolated both Mabs and M. simiae continued to isolate M. simiae despite appearing to clear Mabs. Changing patterns of isolation of Mabs from CF sputum for each individual pwCF across the study period. Isolates of NTM are shown from 1 and 2 years pre- and post-ETI initiation on an individual basis. Each pwCF is delineated in the figure (Mabs n=13; Mabs/M. simiae n=1; M. intracellulare and other NTM n=6). ETI, elexacaftor/tezacaftor/ivacaftor; Mabs, Mycobacterium abscessus; NTM, non-tuberculous mycobacteria; pwCF, people with cystic fibrosis. Within the cohort analysed in this study, 6/13 (46.2%) pwCF isolating Mabs and only 1/3 (33.3%) of pwCF isolating M. intracellulare had previously received directed antimicrobial therapy following confirmation of NTM-PD. None of the pwCF isolating any of the other NTM species, including the pwCF isolating both Mabs/M. simiae, had received treatment for NTM-PD in the past. To date, only one pwCF in our cohort has commenced treatment for NTM-PD, for Mabs infection, following the commencement of ETI. We next evaluated the relationship between culture positivity and clinical indices, such as FEV1 % predicted (adjusted for height, sex and age; ppFEV1) and BMI trajectories during the study period, in relation to ETI treatment. In both the Mabs and M. intracellulare/other NTM species cohorts, increases in ppFEV1 and BMI seen with ETI were similar overall when comparing culture negative to culture positive pwCF (figure 4). Comparison of change in lung function and BMI in pwCF who remain culture positive vs culture negative post initiation of ETI. No statistically significant difference was observed in either FEV1 % predicted (ppFEV1) or BMI (kg/m2) between pwCF who were culture negative compared with those pwCF continuing to isolate NTM species. This was observed for both Mabs ((A) change in ppFEV1, ((B) change in BMI; blue culture negative, red culture positive, green unclear) and MAC and other NTM species ((C) change in ppFEV1, (D) change in BMI; green culture negative, yellow culture positive, orange unclear). There was also no significant difference between those pwCF with an ‘unclear status’ owing to a lack of microbiological/mycobacterial samples since ETI initiation. Simple linear regression was used to calculate the change in either ppFEV1 or BMI over the course of the treatment period with ETI, t-test used to analyse statistical significance between the two groups analysed in each panel. *Denotes pwCF isolating both Mabs/M. simiae. BMI, body mass index; ETI, elexacaftor/tezacaftor/ivacaftor; Mabs, Mycobacterium abscessus; MAC, M. avium complex; ns, non-significant; NTM, non-tuberculous mycobacteria; pwCF, people with cystic fibrosis. Finally, of the pwCF isolating an NTM species during this study, 10 (50%) were either receiving azithromycin or had been treated with it previously, as part of routine CF care.13 Six of these pwCF had isolated Mabs and four either M. intracellulare or another NTM species. Cessation of macrolide therapy treatment occurred in seven as a direct result of isolating an NTM species (70%; four Mabs and three M. intracellulare or other NTM). The remaining three pwCF continuing to receive azithromycin had been continued on azithromycin therapy for its immunomodulatory and anti-inflammatory effects irrespective of NTM status. Discussion Our study found there was no statistically significant difference in the rates of NTM isolation from sputum over the first 2 years of ETI therapy in our cohort of pwCF compared with the 2 years prior to initiation of ETI. However, when considering the changes at a species level, within the limitation of relatively small patient numbers, an apparent clearance of M. intracellulare was evident, while the rates of Mabs isolation remained static over the 4-year period of analysis. Ideally, a comparison to a control group not receiving ETI would have been optimal. However, the low numbers of pwCF meeting these criteria meant that it was not possible to conduct this comparison. Nonetheless, it is worth considering the potential difference seen between the numbers of pwCF continuing to isolate Mabs in comparison to M. intracellulare and other NTM species. Perhaps the reason for this difference could be related to the tenaciousness of Mabs as a pathogenic organism in pwCF, particularly with respect to the subspecies, M. abscessus sp. abscessus, which was the predominant NTM pathogen isolated in our cohort. There was no overt difference in baseline lung function (FEV1, % predicted) for those pwCF isolating Mabs and M. intracellulare or other NTM species, suggesting that disease severity was not an obvious associated factor with NTM status post-ETI therapy. Importantly, there was no statistically significant decline in the number of sputum samples collected across the 4-year period of analysis. However, the variability in sputum sampling rates, although statistically unchanged, needs to be considered further. While it is probable that sputum sampling would have been more rigorous and targeted in the post-ETI phase owing to the nature of this study compared with standard of care, there were still problems experienced with sampling pwCF consistently. Therefore, while participation in the study might account for the apparent increase in sputum sampling for certain pwCF in the post-ETI treatment period, other factors such as the first 2 years of the timeframe analysed correlating with the global COVID-19 pandemic are likely to have impacted on collection opportunities at outpatient clinics due to reductions in in-person attendances. Despite these considerations, the fact that the rates of sputum sampling in our cohort remained stable across the study period is particularly relevant given the concerns within the CF community about the ability to adequately sample pwCF longitudinally for surveillance of the lung microbiota in the era of ETI therapy. That said, there were still several pwCF each year who underwent no sputum sampling, impacting on the ability to accurately determine their longitudinal NTM status in the setting of ETI therapy. This was felt potentially to be due to four reasons: (i) a lack of ability to self-expectorate following ETI initiation; (ii) a reluctance from some pwCF to undergo induced sputum in such circumstances; (iii) geographical and logistical challenges with postal sputum sampling for rural and remote individuals; and (iv) increasing rates of non-attendance as the study progressed presumed to be because of improving health status with ETI and a reluctance to attend the outpatient setting impacting on sampling opportunities. Our data differ from other recently published studies on NTM isolation in pwCF following the initiation of ETI. These have tended to show statistically significant declines in the infection rates of all NTM species, including Mabs.7 In addition, there are isolated case reports detailing apparent sputum culture conversion in previously treatment refractory disease in pwCF initiated on ETI.11 Anecdotally, we also have one pwCF with Mabs cavitatory NTM-PD who has shown remarkable improvements in radiological disease burden without the requirement for antibiotic therapy following the initiation of ETI.14 However, whether the radiological improvement represents clearance of Mabs infection in this pwCF has not yet been established. In contrast, to date, we have also had new acquisitions of NTM in four pwCF since being established on ETI in addition to one pwCF requiring initiation of NTM-PD targeted therapy due to a deteriorating radiological and clinical condition despite receiving over 4 years of ETI therapy.15 All these pwCF, except one, had either moderate or severely reduced FEV1 levels, indicative of more severe baseline disease. It is worth noting that, to date, the four novel acquisitions of NTM remain off treatment, with all continuing under close clinical and microbiological surveillance. All four of the novel acquisitions underwent evaluation with high resolution CT imaging, with only one showing features felt potentially in keeping with NTM-PD. In the absence of associated symptoms, the decision was made to observe this individual. This suggests, although significantly limited by our cohort size, that caution must be observed when managing pwCF infected with Mabs in the setting of ETI. It remains a significant pathogen with marked associated morbidity and an ongoing risk of disease progression or recurrence despite ETI therapy. Another important factor that may contribute to unchanged rates of Mabs within our cohort could be environmental, with recent published data demonstrating an increasing rate of NTM isolation in all groups of people in subtropical/tropical Queensland.12 Certainly, geographical factors such as humidity or evapotranspiration could potentially play an important role with the majority of Queensland’s population living in coastal sub-tropical or tropical areas.16 Furthermore, there has been recent evidence of clonal infection of Mabs via drinking water across Queensland, suggesting this as a reservoir for Mabs and a potential vector in the chain of infection.17 However, it is highly likely that the experiences in other regions of Australia and, indeed, globally, will differ significantly in terms of rates of NTM isolation compared with our cohort and experience. At present, it remains unclear how many pwCF isolating Mabs will go on to require targeted antibiotic therapy. While the number of pwCF in our cohort isolating Mabs remained unchanged post-ETI, only one has progressed to requiring NTM-PD targeted antibiotic therapy. This primarily reflects the degree of clinical stability these pwCF exhibit despite ongoing Mabs isolation and a degree of reluctance to embark on an antibiotic intervention associated with high rates of treatment failure combined with the high side-effect burden.18 19 There is also a lack of clarity regarding the optimal treatment strategy for Mabs, despite the publication of clinical practice guidelines by the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) in 2007, British Thoracic Society (BTS) in 2018 and the ATS/European Respiratory Society (ERS)/European Society of Clinical Microbiology and Infectious Diseases (ESCMID)/IDSA in 2020.20,22 However, what remains clear from our study is that it is critically important to continue close follow-up of pwCF established on ETI therapy, especially if they have evidence of continued NTM culture positivity despite ETI. Additionally, ongoing regular (3 monthly) sputum surveillance for NTM for all pwCF established on ETI should be attempted given the ongoing risk of novel NTM acquisition. This is particularly the case for those pwCF with more severe PD. Reassuringly, clinical stability was maintained by the pwCF in our cohort, as highlighted by ppFEV1 and BMI, with there being no statistically significant differences noted between the pwCF in our cohort who had culture converted, confirmed on sufficient mycobacterial sampling, compared with those who have continued to isolate NTM pathogens, including Mabs. This is most likely related to the overall impact of ETI on the airways and host immune system with improved CFTR function resulting in improved mucous hydration, sputum clearance, ciliary motility and potentially neutrophil and macrophage function.8 9 All of these factors may allow the CF host to keep Mabs ‘under control’ without any of the hallmarks of classical disease developing, potentially by suppressing the growth of NTM in the setting of improved CFTR function similar to what is seen in other pathogens such as P. aeruginosa.10 While the clinical stability of pwCF in our study is inherently positive and reassuring, the data from our CF centre suggest that utilisation of ETI as a ‘stand-alone’ treatment for Mabs should be viewed with a degree of reservation if eradication of infection is the desired outcome. Additionally, the assumption of infection should be maintained for purposes of clinic segregation and infection control in the absence of regular microbiological sampling. However, it is worth noting the potential limitations of our study when considering these points, specifically relating to the combined analysis of a retrospective pre-ETI cohort and a prospective post-ETI cohort highlighted previously. Particularly, given that it is possible that less robust microbiological data were available for the retrospective cohort, however, given the significant burden of NTM in the CF population in Queensland, regular sputum surveillance has been standard of care for many years. It was therefore felt unlikely that this would have influenced our results, though we cannot completely discount the possibility. An interesting observation was that all pwCF previously isolating M. intracellulare appear to have sustained culture conversion on ETI, whereas other NTM species persisted. One pwCF has continued to isolate M. simiae, again without any hallmarks of radiological disease and not requiring treatment, with another individual regularly isolating M. fortuitum, again without the requirement for any antibiotic treatment despite persistent culture positivity. Whether these rates of isolation will change in the future again remains unclear and regular ongoing sputum sampling for NTM species remains paramount, especially in those pwCF with previous history of isolation of NTM. In summary, there was a trend in the reduction of isolations of M. intracellulare and other NTM species in our CF cohort following ETI initiation. However, the rates of Mabs isolation remain broadly unchanged. The introduction of ETI has maintained clinical stability in these pwCF, with only one pwCF progressing to requiring antibiotic treatment for NTM-PD to date. No statistical differences in clinical trajectory between culture negative and culture positive pwCF were noted. However, ongoing close observation of all these pwCF is recommended for now with more long-term data in larger numbers of pwCF required to establish whether this represents a truly sustained reduction in rates of NTM secondary to ETI treatment. In the centres evaluated by this study, pwCF who have isolated Mabs will continue to undergo regular sputum surveillance, with a minimum of four samples per year, and interval CT imaging in the setting of a clinical deterioration. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Patient consent for publication: Not applicable. Ethics approval: This study involved human participants. The ethical approval for the study was obtained from the Metro North Health Human Research Ethics Committee (HREC/2019/QPCH/46169). Participants gave informed consent to participate in the study before taking part. Provenance and peer review: Not commissioned; externally peer-reviewed. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Data availability statement No data are available. References Associated Data Data Availability Statement No data are available.